Schizophrenia/Psychosis

Explore the evolving landscape of psychiatric diagnosis and treatment, highlighting the gap between evidence-based standards and real-world practices.

International guidelines for schizophrenia treatment standardize care, addressing disparities and emphasizing proactive metabolic management for better patient outcomes.

Alto Neuroscience's ALTO-101 gains FDA fast track designation, promising a novel treatment for cognitive impairment in schizophrenia.

In this CME article, explore the complexities of movement disorders in psychiatric practice, including their causes, symptoms, and treatment strategies for better patient care.

A new study reveals the overwhelming financial and emotional burdens faced by caregivers of individuals with schizophrenia, highlighting urgent support needs.

Alto Neuroscience pioneers drug development for cognitive impairment in schizophrenia, targeting biomarkers to enhance treatment precision and patient outcomes.

New research highlights the effectiveness of early psychosis intervention programs, emphasizing low caseloads and clozapine access to reduce relapse rates.

It is time to redefine treatment resistance, a definition in which we emphasize comprehensive evaluations and personalized approaches for better patient outcomes.

Alto Neuroscience reveals EEG biomarkers effectively distinguish patients with schizophrenia, enhancing treatment precision and advancing psychiatric research.

FDA approves Amneal Pharmaceuticals' new long-acting injectable risperidone for schizophrenia, enhancing treatment options and potentially patient adherence.

Exploring the prevalence and implications of psychotropic polypharmacy in patients taking clozapine with treatment-resistant schizophrenia.

Explore the complex interplay of genetics, environment, concussion, substance abuse, and inflammation in severe mental illnesses, revealing critical insights for prevention and treatment.

Care partners for patients with schizophrenia can greatly benefit from psychoeducation provided by clinicians.

BioXcel Therapeutics reveals promising phase 3 results from the SERENITY trial, paving the way for potential at-home treatment of agitation in bipolar disorder and schizophrenia.

Dive into the forms of assessment for cognitive dysfunction in relation to the diagnosis and treatment of schizophrenia.

Panelists discuss how successful implementation of xanomeline/trospium chloride requires understanding its unique mechanism of action, providing proper patient education about dosing requirements, starting with slow titration, and recognizing it as an early treatment option rather than a last resort.

BioXcel Therapeutics advances BXCL501 for at-home treatment of agitation in bipolar disorders and schizophrenia, aiming for FDA approval by 2026.

Clinician's can use the new international guidelines for schizophrenia treatment to solidify treatment decisions and improve patient outcomes.

Nearly half of catatonia patients relapse within two years, highlighting the need for effective long-term management strategies and potential benefits of antipsychotics.

BioXcel Therapeutics advances BXCL501 for outpatient treatment of agitation in bipolar disorder and schizophrenia, receiving positive FDA feedback in its pre-sNDA meeting discussion.

Panelists discuss how best practices involve starting with lower doses in older patients, considering long-term tolerability over acute symptom control, and potentially using xanomeline/trospium chloride as first-line treatment even for treatment-naive patients presenting with acute psychosis.

Panelists discuss how Lila’s late-onset schizophrenia at age 52 raises diagnostic concerns requiring thorough medical workup, and how her response to olanzapine with sedation and shakiness suggests the need for dose reduction or consideration of alternative treatments such as xanomeline/trospium chloride.

AI chatbots pose significant mental health risks, often exacerbating issues like suicide, self-harm, and delusions, highlighting urgent regulatory needs.

UK study of "active ingredients" in early psychosis intervention is applicable to US programs, according to the codirector of Stanford's INSPIRE Clinic.